d-Fenfluramine-induced prolactin responses in mania: Evidence for serotonergic subsensitivity

American Journal of Psychiatry

Volumn 153, Issue 11, 1996, Pages 1460-1463

  Thakore, Jogin H ^a   O'Keane, Veronica ^b   Dinan, Timothy G ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FENFLURAMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; MANIA; MANIC DEPRESSIVE PSYCHOSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROLACTIN RELEASE; SEROTONIN RELEASE; SEROTONIN UPTAKE;

EID: 0029917357     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.11.1460     Document Type: Article

References (46)

1. Maes M, Meltzer HY: The serotonin hypothesis of major depression, in Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York, Raven Press, 1994, pp 933-944
2. Meagher JB, O'Halloran A, Carney PA, Leonard BE: Changes in platelet 5-hydroxytryptamine uptake in mania. J Affect Disord 1990; 19:191-196
3. Scott M, Reading HW, Louden JB: Studies on human platelets in affective disorders. Psychopharmacology (Berl) 1979; 60:131-135
4. Meltzer HY, Arora RC, Baher R, Tricou BJ: Serotonin uptake in blood platelets of psychiatric patients. Arch Gen Psychiatry 1981; 38:1322-1326
5. Coppen AJ: Indoleamines and the affective disorders. J Psychiatr Res 1972; 9:163-171
6. Banki CM: Correlation between CSF metabolites and psychomotor activity in affective disorders. J Neurochem 1977; 28:255-257
7. Koslow SH, Maas JW, Bowden CL, Davies JM, Hanin J, Javaid J: CSF and urinary biogenic amines and metabolites in depression and mania: a controlled univariate analysis. Arch Gen Psychiatry 1983; 40:999-1010
8. Bowers MB, Heninger GR, Gerbode FA: Cerebrospinal fluid 5-HIAA and HVA in psychiatric patients. Int J Neuropharmacol 1969; 8:155-162
9. Goodwin FK, Post RM: Studies of amine metabolites in affective illness and in schizophrenia: a comparative analysis, in Biology of the Major Psychoses. Edited by Freedman DX. New York, Raven Press, 1975, pp 299-332
10. Ashcroft G, Dow R, Yates C: Significance of lumbar CSF metabolite measurements in affective illness, in CNS and Behavioural Pharmacology. Edited by Tuomisto J, Paasonen M. Helsinki, Helsinki University Press, 1976, pp 277-284
11. Gerner RH, Fairbanks L, Anderson GM, Young JG, Scheinin M, Linnoila M, Hare TA, Shaywitz BA, Cohen DJ: CJSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. Am J Psychiatry 1984; 141:1533-1540
12. Young LT, Warsh JJ, Kish SJ, Shannak K, Hornykeiwicz O: Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol Psychiatry 1994; 35:121-127
13. Kuruvilla A, Srikrishna G, Peedicayil J, Kuruvilla K, Kanagasabathy AS: Serum prolactin levels in manic patients. Biol Psychiatry 1991; 30:421-423
14. Linkowski P, Kerkhofs M, Van Onderbergen A, Hubain P, Copinschi G, L'Hermite-Baleriaux M, Leclerc R, Brasseur M, Mendlewicz J, van Cauter E: The 24-hour profiles of cortisol, prolactin, and growth hormone secretion in mania. Arch Gen Psychiatry 1994; 51:616-624
15. Yatham LN: Buspirone induced prolactin release in mania. Biol Psychiatry 1994; 35:533-536
16. O'Keane V: Dynamic serotonin neuroendocrine challenges in depressive disorders: what have we learnt? J Serotonin Res 1994; 1:101-111
17. Garattini S, Mennini T, Samanin R: From fenfluramine racemate to d-fenfluramine. Ann NY Acad Sci 1987;499:156-166
18. Gorard DA, Taylor TM, Medbak SH, Perry LA, Libby GW, Farthing MJ: Plasma prolactin, adrenocorticotropic hormone and cortisol after administration of d-fenfluramine or placebo to healthy subjects. Int Clin Psychopharmacol 1993; 8:123-128
19. Petterson U, Fyro B, Sedvall G: A new scale for the longitudinal rating of manic states. Acta Psychiatr Scand 1973; 49:248-256
20. O'Keane V, Dinan TG: Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function. Am J Psychiatry 1991; 148:1009-1015
21. Lovgren T, Hemmilia I, Petterson K: Resolved fluorometry in immunoassays, in Alternative Immunoassays. Edited by Collins WP. London, John Wiley & Sons, 1985, pp 52-69
22. Dash RJ, England BG, Rees Midgley A Jr: A specific, nonchromatographic radioimmunoassay for human plasma cortisol. Steroids 1975; 26:647-661
23. Statistical Graphics Corporation: Statgraphics, Version 2.7. New York, Statistical Graphics Corp, 1987
24. Peroutka SJ: Selective interaction of novel anxiolytics with 5-hydroxytryptamine 1a receptors. Biol Psychiatry 1985; 20:971-979
25. Eison AS, Temple DL Jr: Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am J Med 1986; 80(March suppl):1-9
26. Coccaro EF, Gabriel S, Mahon T, Macaluso J, Siever LJ: Preliminary evidence of a serotonin (5-HT-1-like) component to the prolactin response to buspirone challenge in humans (letter). Arch Gen Psychiatry 1990; 47:594-495
27. Meltzer HY, Lee HS, Nash JF Jr: Effect of buspirone on prolactin secretion is not mediated by 5-HT1a receptor stimulation. Arch Gen Psychiatry 1992; 49:163-164
28. Curtis D, Brynjolfsson J, Petursson H, Holmes DS, Sherrington R, Brett P, Rifkin L, Murphy P, Moloney P, Moloney E, Holmes S: Segregation and linkage analysis in five Bipolar manic depression pedigrees excludes the 5HT1a receptor gene (HTR 1A). Ann Hum Genet 1993; 57:27-39
29. Jorgensen H, Knigge U, Warberg J: Involvement of 5-HT1, 5-HT2 and 5-HT3 receptors in the mediation of the prolactin response to serotonin and 5-hydroxytryptophan. Neuroendocrinology 1992; 55:336-343
30. Leung FC, Chen HT, Verkaik SJ, Steger RW, Peluso JJ, Campbell GA, Meites J: Mechanism by which adrenalectomy and corticosterone influence prolactin release in the rat. J Kndocrinol 1980; 87: 131-140
31. Lamberts SW, van Koetsveld P, Verleun T: Prolactin release-inhibitory effects of progesterone, megesterol acetate, and mifepristone (RU 38486) by cultured ral pituitary tumor cells. Cancer Res 1987; 47:3667-3671
32. Ooesterom O, Verleun T, Zuiderwijk J, Uitterlinden P, Lamberts SW: Effect of long-term corticosteroid administration on rat pituitary growth hormone and prolactin. Acta Endocrinol 1985; 108:475-478
33. Lopez-Calderon A, Ariznavarreta C, Calderon MD, Tresguerres JAF, Gonzalez-Quijano MJ: Role of the adrenal cortex in chronic stress-induced inhibition of prolactin secretion in male rats. J Endocrinol 1989; 120:269-273
34. Bartha L, Nagy GM, Kiem DT, Fekete MI, Makara GB: Inhibition of suckling-induced prolactin release by dexamethasone. Endocrinology 1991; 129:635-640
35. Dickenson SL, Kennett GA, Curzon G: Reduced 5-hydroxytryptamine-dependent behaviour in rats following chronic corticosterone treatment. Brain Res 1983; 345:10-18
36. Klein HE, Seibold B, Bender W, Nedopil N, Albus M, Schmauss M: Postdexamethasone prolactin and Cortisol: a biological state variable in depression. Acta Psychiatr Scand 1984; 70:239-247
37. Rupprecht R, Barocka E, Jecht M, Norder M, Prichl J, Schwarz W: Prolactin response to dexamethasone: a study on normal controls and depressed patients. Acta Psychiatr Scand 1987; 76: 139-143
38. Thakore JH, Dinan TG: Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression. Biol Psychiatry 1995; 37:364-368
39. Lopez-Ibor JJ, Saiz-Ruiz J, Iglesias M: The fenfluramine challenge test in the affective spectrum: a possible marker of endogenicity and severity. Pharmacopsychiatry 1988; 21:9-14
40. Mitchell P, Smythe G: Hormonal responses to fenfluramine in depressed and control subjects. J Affect Disord 1990; 19:43-51
41. O'Keane V, McLoughlin D, Dinan TG: d-Fenfluramine-induced prolactin and cortisol release in major depression: response to treatment. J Affect Disord 1992; 26:143-150
42. Ansseau M, von Frenckell R, Cerfontaine J-L, Papart P, Franck G, Timsit-Berrhier M, Geenen V, Legros JJ: Neuroendocrine evaluation of catecholaminergic function in mania. Psychiatry Res 1988; 22:193-206
43. Dinan TG, Yatham LN, O'Keane V, Barry S: Blunting of noradrenergic-stimulated growth hormone release in mania. Am J Psychiatry 1991; 148:936-938
44. Dinan TG, Barry S: Responses of growth hormone to desipramine in endogenous and non-endogenous depression. Br J Psychiatry 1990; 156:680-684
45. Dinan TG, O'Keane V, Thakore J: Pyridostigmine induced growth hormone release in mania: focus on the cholinergic/somatostatin system. Clin Endocrinol 1994; 40:93-96
46. O'Keane V, O'Flynn K, Lucey J, Dinan TG: Pyridostigmine-induced growth hormone responses in healthy and depressed subjects: evidence for cholinergic supersensitivity in depression. Psychol Med 1992; 22:55-60